Mechanisms of cisplatin ototoxicity and progress in otoprotection

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 15, Issue 5, 2007, Pages 364-369

  Rybak, Leonard P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Cisplatin; Otoprotection; Ototoxicity

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; ACETYLCYSTEINE; ADENOSINE A1 RECEPTOR AGONIST; ADENOVIRUS VECTOR; ALLOPURINOL; ALPHA TOCOPHEROL; AMIFOSTINE; AMINOGUANIDINE; BUTHIONINE SULFOXIMINE; CASPASE 3 INHIBITOR; CASPASE 9 INHIBITOR; CISPLATIN; DIETHYLDITHIOCARBAMIC ACID; EBSELEN; FLUNARIZINE; GINKGO BILOBA EXTRACT; METHIONINE; PIFITHRIN ALPHA; PIPERINE; SALICYLATE SODIUM; SALICYLIC ACID DERIVATIVE; SODIUM THIOSULFATE; SURAMIN; THIOCTIC ACID; TIOPRONIN; X LINKED INHIBITOR OF APOPTOSIS;

ALLELE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COCHLEA; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; EAR PROTECTION; ENZYME PHOSPHORYLATION; GENETIC PREDISPOSITION; GENOTYPE; GERM CELL TUMOR; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; INNER EAR; LIPID OXIDATION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; TESTIS CANCER; UPREGULATION; UTERINE CERVIX CANCER; VOMITING;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CISPLATIN; GENETIC PREDISPOSITION TO DISEASE; HEARING LOSS, SENSORINEURAL; HUMANS; NEUROPROTECTIVE AGENTS; RISK FACTORS;

EID: 34548485284     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e3282eee452     Document Type: Review

References (52)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-320.
2. Buhrer C, Weinel P, Sauter S, et al. Acute onset deafness in a 4-year-old girl after a single infusion of cis-platinum. Pediatr Hematol Oncol 1990; 7:145-148.
3. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77:1355-1362.
4. Biro K, Nozsek L, Prekopp P, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 2006; 70:177-184.
5. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25:1190-1195.
6. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13:228-244.
7. Kushner BH, Budnick A, Kramer K, Modak S, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107:417-422. This article demonstrates the severity and pervasiveness of ototoxicity in this population of pediatric patients treated with cisplatin and stresses the need for strategies to ameliorate cisplatin ototoxicity.
8. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin in childhood cancer. Pediatr Hematol Oncol 2007; 29:355-360.
9. Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head and neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 2007; 5 April [Epub ahead of print].
10. Zuur CL, Simis YJW, Lansdaal PEM, et al. Audiometric patterns in otoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurotol 2006; 11:318-330.
11. Chen WC, Jackson A, Budnick A, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006; 106:820-829.
12. Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990; 100:724-734.
13. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: influence of age and the cumulative dose. Eur J Cancer 2004; 40:2445-2451.
14. Peters U, Preisler-Adams S, Lanvers-Kaminsky C, et al. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 2003; 23:1249-1255.
15. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione-s- transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25:708-714. This article demonstrates the association of mutations in the genes coding for glutathione-s-transferase genotypes and describes how the inability to metabolize cisplatin may result from these genetic changes, making these patients more susceptible to cisplatin ototoxicity.
16. Thomas JP, Lautermann J, Liedert B, et al. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharm 2006; 70:23-29. This paper demonstrates the localization of platinum-DNA adducts in the cochlea.
17. Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics 2007; 24 April [Epub ahead of print].
18. Clerici WJ, DiMartino DL, Prasad MR. Direct effect of reactive oxygen species on cochlear outer hair cells. Hear Res 1995; 84:30-40.
19. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin induced ototoxicity and prevention. Hear Res 2007; 226:157-167.
20. Lee JE, Nakagawa T, Kita T, et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol 2004; 124:1131-1135.
21. Alam SA, Ikeda K, Oshima T, et al. Cisplatin-induced apoptotic cell death in Mongolian gerbil. Hear Res 2000; 141:28-38.
22. Banfi B, Malgrange B, Knisz J, et al. Nox3, a superoxide- generating NADPH oxidase of the inner ear. J Biol Chem 2004; 279:46065-46072.
23. Mukherjea D, Whitworth CA, Nandish S, et al. Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. Neuroscience 2006; 139:733-740. This article is the first to demonstrate the presence of KIM-1 in cochlear cells in vitro and in vivo and how it is upregulated by cisplatin.
24. Watanabe K, Inai S, Jinnouchi K, et al. Expression of caspase-activated deioxyribonuclease (CAD) and caspase-3 (CPP32) in the cochlea of cisplatin (CPPD)-treated guinea pigs. Auris Nasis Larynx 2003; 30:219-225.
25. Wang J, Ladrech S, Pujol R, et al. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res 2004; 64:9217-9224.
26. Previati M, Lanzoni I, Astolfi L, et al. Cisplatin cytotoxicity in organ of Corti derived immortalized cells. J Cell Biochem 2007; 22 January [Epub ahead of print].
27. So H, Kim H, Lee JH, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol 2007; 22 May [Epub ahead of print]. This article describes a potential role for TNF-α and interleukins in cisplatin ototoxicity.
28. Kopke RD, Liu W, Gabaizadeh R, et al. The use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin induced damage of auditory hair cells. Am J Otol 1997; 18:559-571.
29. Dickey TD, Muldoon LL, Kraemer DF, Neuwelt EA. Protection against cisplatin ototoxicity by N-acetylcysteine in a rat model. Hear Res 2004; 193:25-30.
30. Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004; 25:910-915.
31. Whitworth CA, Ramkumar V, Jones B, et al. Protection against cisplatin ototoxicity by adenosine agonists. Biochem Pharmacol 2004; 67:1801-1807.
32. Cunningham L, Brandon CS. Heat shock inhibits both aminoglycoside- and cisplatin-induced sensory cell death. J Assoc Res Otolaryngol 2006; 7:299-307.
33. Bach FH. Heme oxygenase-1: a therapeutic amplification funnel. FASEB J 2005; 19:1216-1219.
34. Kim HJ, So HS, Lee JH, et al. Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic Biol Med 2006; 40:1810-1819.
35. Choi B-M, Kim S-M, Park T-K, et al. Piperine protects cisplatin-induced apoptosis via heme oxygenase-1 induction in auditory cells. J Nutr Biochem 2007; 4 April [Epub ahead of print].
36. Li G, Sha SH, Zotova E, et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 2002; 82:585-596.
37. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 2004; 65:490-499.
38. So H-S, Kim HJ, Lee JH, et al. Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ 2006; 13:1763-1775. This article demonstrates a link between the protective effect of flunarizine against cisplatin ototoxicity and HO-1 induction in cochlear cells in vitro.
39. Zhang M, Liu W, Ding D, Salvi R. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 2003; 120:191-205.
40. Chan DK, Lieberman DM, Musatov S, et al. Protection against cisplatin-induced ototoxicity by adeno-associated virus-mediated delivery of the X-linked inhibitor of apoptosis protein is not dependent on caspase inhibition. Otol Neurotol 2007; 28:417-425.
41. Jeong H-J, Kim S-J, Moon P-D, et al. Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the HeI-OC1 auditory cell line. J Neurosci Res 2006; 85:896-905.
42. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discovery Today 2005; 10:1313-1321.
43. Campbell KCM, Meech RP, Klemens JJ, et al. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res 2007; 226:92-103. This article describes the protective actions of D-methionine against noise, aminoglycoside- and cisplatin-induced ototoxicity both with parenteral and oral administration in rats.
44. Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005; 201:81-89.
45. Lynch ED, Gu R, Pierce C, Kil J. Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing antitumor activity. Anticancer Drugs 2005; 16:569-579.
46. Huang X, Whitworth CA, Rybak LP. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol Neurotol 2007; 19 April [Epub ahead of print].
47. Videhult P, Laurell G, Wallin I, Ehrsson H. Kinetics of cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. Exp Biol Med (Maywood) 2006; 231:1638-1645.
48. Van den Berg JH, Beijnen JH, Balm AJM, Schellens JHM. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006; 32:390-397.
49. Church MW, Blakley BW, Burgio DL, Gupta AK. WR-2721 (amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters. J Assoc Res Otolaryngol 2004; 5:227-237.
50. Ekborn A, Hansson J, Ehrsson H, et al. High dose cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 2004; 114:1660-1667.
51. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 2005; 104:841-847.
52. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 2005; 22:441-445.